| Literature DB >> 16023406 |
H-C Mundt1, B Bangoura, M Rinke, M Rosenbruch, A Daugschies.
Abstract
Two studies were conducted in the Eimeria zuernii infection model in order to investigate the pathology of E. zuernii coccidiosis and the efficacy of toltrazuril (Baycox 5% suspension) in this infection. For this purpose, a total of 30 calves were infected experimentally with E. zuernii oocysts and faecal samples taken regularly from the rectum and examined for faecal consistency and oocyst excretion. Six of the calves underwent pathological examination at various points in time after infection. Significant macroscopic and microscopic changes were demonstrated and parasitic stages were identified in the intestinal mucosa of infected calves during the late prepatent and patent period. Inflammatory reactions revealed by light microscopy were confirmed by electron microscopical investigations. Treatment of calves with toltrazuril during the late prepatent period resulted in significantly lower frequencies of diarrhoea and levels of oocyst excretion, and weight gain was significantly higher than in shamtreated animals.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16023406 PMCID: PMC7185487 DOI: 10.1016/j.parint.2005.06.003
Source DB: PubMed Journal: Parasitol Int ISSN: 1383-5769 Impact factor: 2.230
Schedule of the studies (dpi = day post infectionem)
| Study I | Group/no. | Sampling day | Parameters assessed (groups A–C) |
|---|---|---|---|
| Infection with 150,000 sporulated | A/2 | 16 dpi (late prepatent period) | –clinical and parasitological parameters until pathological examination: see Study II |
| B/2 | 21 dpi (patent period) | –pathologic-anatomical and histopathological findings in the mucosa | |
| C/2 | 26 dpi (late patent period/early postpatency) | ||
| Study II | Group/no. | Treatment | Parameters assessed (groups A–C) |
| Infection with 150,000 sporulated | D/12 | Toltrazuril (15 mg/kg, day 14 after infection) | –Clinical examination: daily |
| E/11 | -(sham dosing with water, day 14 after infection) | –Faecal consistency and oocyst excretion: on 0, 2, 5, 7, 9, 12 and 15–32 dpi | |
Oocyst excretion of groups B (n = 2), C (n = 2), D (n = 12) and E (n = 11) of Studies I and II, characterized by median of the opg (oocysts per gram), minimum opg and maximum opg in the respective group (data for previous faecal oocyst counts is not given in this table, in all faecal examinations on 0–14 dpi (day post infectionem) no oocysts were detected); *: na = not applicable (animals sacrificed)
| Study | dpi | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study I | Median opg of group B | 0 | 0 | 1200 | 1650 | 3500 | 35,925 | na* | na | na | na | na | na | na | na | na | na | na | na |
| Minimum opg of group B | 0 | 0 | 0 | 0 | 900 | 21,400 | na | na | na | na | na | na | na | na | na | na | na | na | |
| Maximum opg of group B | 0 | 0 | 2400 | 3300 | 6100 | 50,450 | na | na | na | na | na | na | na | na | na | na | na | na | |
| Median opg of group C | 150 | 1475 | 5025 | 8700 | 10,425 | 5200 | 27,350 | 8150 | 5200 | 5000 | 25 | na | na | na | na | na | na | na | |
| Minimum opg of group C | 0 | 0 | 0 | 0 | 1200 | 750 | 1500 | 6750 | 550 | 400 | 0 | na | na | na | na | na | na | na | |
| Maximum opg of group C | 300 | 2950 | 10,050 | 17,400 | 19,650 | 9650 | 53,200 | 9550 | 9850 | 9600 | 50 | na | na | na | na | na | na | na | |
| Study II | Median opg of group D | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minimum opg of group D | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Maximum opg of group D | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Median opg of group E | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 100 | 450 | 650 | 300 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Minimum opg of group E | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Maximum opg of group E | 0 | 0 | 8850 | 9950 | 20,550 | 2750 | 77,850 | 6750 | 18,400 | 5400 | 13,800 | 3300 | 123,100 | 32,600 | 200 | 200 | 0 | 50 |
Weight gain of groups D (n = 12) and E (n = 11) of Study II—arithmetic means (mean) and standard deviations (SD) of weekly live weight measurements
| Group | dpi | 0 | 7 | 14 | 21 | 28 |
|---|---|---|---|---|---|---|
| D | mean ± SD | 54.9 ± 4.5 | 61.0 ± 5.3 | 65.7 ± 5.9 | 69.5 ± 6.1 | 75.3 ± 6.6 |
| E | mean ± SD | 52.1 ± 5.0 | 56.8 ± 5.4 | 62.2 ± 6.1 | 65.2 ± 5.8 | 68.3 ± 6.6 |
Fig. 1Light microscopical findings. (a) Crypt of the caudal jejunum with parasitic structures (second generation schizont, arrow above), crypt with granulocytic infiltration (arrow below) in animals during the prepatent period. H&E, Obj. 40 ×. (b) Cecal mucosa with second generation schizonts (left arrow) and oocysts (right arrow) in animals during the patent period. H&E, oil immersion, 100 ×. (c) Acute parasitic typhlitis, crypts filled with parasitic structures (right arrow), increased numbers of inflammatory infiltrates (middle arrow). Note loss of superficial epithelium (arrow above). H&E, Obj. 10 ×.
Fig. 2Electron microscopical findings. (a) Normal appearance of the ileum in animals during the prepatent period. (b) Superficial epithelial loss in the cecum of animals during the patent period. (c) Superficial epithelial injury in the ileum of animals during the late patent period.
Fig. 3Distribution of the faecal scores in groups D and E (Study II)-respective quota of the total sample size (on day 0 post infectionem (dpi) one faecal sample was missing in group D). (a) group E (infected, shamtreated control). (b) group D (infected, treated with 15 mg toltrazuril/kg liveweight on 14 dpi).